Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 7/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596222 | 0.94 | TACR2 (0.36) | HRH1TACR2ALDH1A1LMNAMAPT | |
| SCHEMBL6592554 | 0.94 | TACR2 (0.38) | HRH1TACR2TACR1 | |
| SCHEMBL6597168 | 0.93 | TACR2 (0.39) | HRH1TACR2TACR1ALDH1A1LMNA | |
| SCHEMBL8444228 | 0.93 | TACR2 (0.36) | HRH1TACR2TACR1ALDH1A1LMNA | |
| SCHEMBL6597322 | 0.93 | LMNA (0.41) | HRH1TACR2TACR1ALDH1A1LMNA | |
| SCHEMBL6594797 | 0.92 | TACR2 (0.40) | TACR2TACR1MAPT | |
| SCHEMBL6592794 | 0.92 | TACR2 (0.39) | TACR2TACR1ALDH1A1LMNAMAPT | |
| SCHEMBL6598213 | 0.91 | HRH1 (0.41) | HRH1TACR2HTR1ATACR1ALDH1A1 | |
| SCHEMBL6595657 | 0.91 | TACR2 (0.38) | TACR2TACR1ALDH1A1LMNAMAPT | |
| SCHEMBL6597554 | 0.91 | TACR2 (0.39) | TACR2TACR1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888338-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2004-11-17 | — | — | EP | disclosed |